Fig. 5.

The combination of AVA with KVax enhances the inhibition of Kras-driven lung tumors in the Kras^LA1 GEMM model. (a) Experimental design outlining the timing of vaccine, AVA administration, and experimental endpoint (Eut, euthanasia). (b) Tumor multiplicity and tumor volume quantitation at the experimental endpoint. (c) Representative IHC staining and quantitative data for Ki-67 from the Kras^LA1 model lung tumor. (d) Representative IHC staining and quantitative data for tumor-infiltrating CD8+ T cells from the Kras^LA1 model lung tumor. (e) Cytokine analysis by Mouse Cytokine Array/ Chemokine Array 31-Plex (MD31) using supernatant collected from splenocytes stimulated with peptides for 72hr. Data are shown as the mean ± SE, n = 8, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs Ctrl, two-tailed Student's t-test.